FDA Will Use PET And Biomarkers To Speed Drug Development – Gottlieb
This article was originally published in The Gray Sheet
Executive Summary
FDA's "old-fashioned" regulatory processes have "impeded scientific development" in using assays, biomarkers, genomics and positron emission tomography (PET) to speed drug development, according to FDA Deputy Commissioner for Medical and Scientific Affairs Scott Gottlieb, MD
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.